150 related articles for article (PubMed ID: 38008067)
1. Adverse Effects Under Th2 Biologics (Dupilumab and Tezepelumab) in a Patient with Severe Asthma and Atopic Dermatitis.
Suhling H; Hinze CA; Welte T; Werfel T; Traidl S
Respiration; 2023; 102(12):1016-1019. PubMed ID: 38008067
[TBL] [Abstract][Full Text] [Related]
2. [Principles of modern diagnosis and treatment of atopic dermatitis and bronchial asthma: Clinical case].
Shogenova MS; Hutueva SH; Shogenova LS
Ter Arkh; 2022 Mar; 94(3):427-433. PubMed ID: 36286909
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation.
L Ramos C; Namazy J
Immunol Allergy Clin North Am; 2023 Feb; 43(1):187-197. PubMed ID: 36411004
[TBL] [Abstract][Full Text] [Related]
4. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
7. Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis.
Tosca MA; Olcese R; Girosi D; Casalini E; Scaglione M; Ciprandi G
Allergol Immunopathol (Madr); 2023; 51(3):181-185. PubMed ID: 37169576
[TBL] [Abstract][Full Text] [Related]
8. Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.
Matsumoto T; Sakurai Y; Tashima N; Matoba T; Kaneko A; Fujiki T; Kusakabe Y; Nakayama E; Tanaka A; Tashima M; Yamamoto N; Aihara K
Respirol Case Rep; 2024 Jan; 12(1):e01266. PubMed ID: 38074921
[TBL] [Abstract][Full Text] [Related]
9. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab for treatment of atopic dermatitis.
Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab: First Global Approval.
Shirley M
Drugs; 2017 Jul; 77(10):1115-1121. PubMed ID: 28547386
[TBL] [Abstract][Full Text] [Related]
15. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Eichenfield LF; Bieber T; Beck LA; Simpson EL; Thaçi D; de Bruin-Weller M; Deleuran M; Silverberg JI; Ferrandiz C; Fölster-Holst R; Chen Z; Graham NMH; Pirozzi G; Akinlade B; Yancopoulos GD; Ardeleanu M
Am J Clin Dermatol; 2019 Jun; 20(3):443-456. PubMed ID: 31066001
[TBL] [Abstract][Full Text] [Related]
16. Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection.
Brodska P; Panzner P; Sedlacek D; Terl M; Cetkovska P
Dermatol Ther; 2020 Nov; 33(6):e14159. PubMed ID: 32776586
[TBL] [Abstract][Full Text] [Related]
17. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.
Chiarella SE
Allergy Asthma Proc; 2019 Nov; 40(6):485-489. PubMed ID: 31690400
[TBL] [Abstract][Full Text] [Related]
18. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
19. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.
Ratchataswan T; Banzon TM; Thyssen JP; Weidinger S; Guttman-Yassky E; Phipatanakul W
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1053-1065. PubMed ID: 33685604
[TBL] [Abstract][Full Text] [Related]
20. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.
Simpson EL; Parnes JR; She D; Crouch S; Rees W; Mo M; van der Merwe R
J Am Acad Dermatol; 2019 Apr; 80(4):1013-1021. PubMed ID: 30550828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
